{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T09:58:14Z","timestamp":1792835894556,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T00:00:00Z","timestamp":1655078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T00:00:00Z","timestamp":1655078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The impact of strong Programmed Death-ligand 1 (PD-L1) expression on the clinical outcomes of osimertinib in treatment na\u00efve advanced <jats:italic>Epidermal Growth Factor Receptor (EGFR)<\/jats:italic>-mutant Non-small Cell Lung Cancer (NSCLC) patients remains uncertain. We enrolled advanced NSCLC patients who harbored sensitizing <jats:italic>EGFR<\/jats:italic> mutation and were treated first-line with osimertinib between 2017 and 2021. The PD-L1 expression level was also tested. A total of 85 patients were included. The objective response rate to osimertinib was 78.9%, with the disease control rate being 90.8%. Median Progression-free Survival (PFS) was 22.1\u00a0months, while median Overall Survival (OS) was not reached (NR). Patients with the exon 19 deletion experienced better PFS than those with the exon 21 L858R mutation (NR vs 12.4\u00a0months, aHR 0.24 (95% CI, 0.10 to 0.57); <jats:italic>p\u2009<\/jats:italic>=\u20090.001). Seventy-one of these 85 patients had reported on their PD-L1 expression. Patients with a PD-L1\u2009&lt;\u200950% experienced longer PFS than patients with a PD-L1 \u226750% (26.5 vs 9.7\u00a0months, aHR 0.19 (95% CI, 0.06 to 0.67); <jats:italic>p<\/jats:italic>\u2009=\u20090.009). Additionally, patients with a PD-L1\u2009&lt;\u200950% experienced better OS than those with a PD-L1 \u226750% (NR vs 25.4\u00a0months, aHR 0.09 (95% CI, 0.01 to 0.70); p\u2009=\u20090.021). Strong expressions of PD-L1 in treatment na\u00efve advanced <jats:italic>EGFR<\/jats:italic>-mutant NSCLC patients were associated with poor prognoses in those undergoing treatment with osimertinib as first-line therapy.<\/jats:p>","DOI":"10.1038\/s41598-022-13102-7","type":"journal-article","created":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T15:05:52Z","timestamp":1655132752000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["PD-L1 strong expressions affect the clinical outcomes of osimertinib in treatment na\u00efve advanced EGFR-mutant non-small cell lung cancer patients"],"prefix":"10.1038","volume":"12","author":[{"given":"Kuo-Hsuan","family":"Hsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeng-Sen","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsung-Ying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun-Chieh","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang-Yi","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Liang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy J. W.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Hsiang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gee-Chen","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,13]]},"reference":[{"issue":"2","key":"13102_CR1","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1097\/JTO.0000000000000033","volume":"9","author":"Y Shi","year":"2014","unstructured":"Shi, Y. et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J. Thorac. Oncol. 9(2), 154\u2013162 (2014).","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"13102_CR2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0120852","volume":"10","author":"KH Hsu","year":"2015","unstructured":"Hsu, K. H. et al. Identification of five driver gene mutations in patients with treatment-na\u00efve lung adenocarcinoma in Taiwan. PLoS ONE 10(3), e0120852 (2015).","journal-title":"PLoS ONE"},{"issue":"21","key":"13102_CR3","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1056\/NEJMoa040938","volume":"350","author":"TJ Lynch","year":"2004","unstructured":"Lynch, T. J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350(21), 2129\u20132139 (2004).","journal-title":"N. Engl. J. Med."},{"issue":"5676","key":"13102_CR4","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1126\/science.1099314","volume":"304","author":"JG Paez","year":"2004","unstructured":"Paez, J. G. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304(5676), 1497\u20131500 (2004).","journal-title":"Science"},{"issue":"3","key":"13102_CR5","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","volume":"13","author":"R Rosell","year":"2012","unstructured":"Rosell, R. et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 13(3), 239\u2013246 (2012).","journal-title":"Lancet Oncol."},{"issue":"10","key":"13102_CR6","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJMoa0810699","volume":"361","author":"TS Mok","year":"2009","unstructured":"Mok, T. S. et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361(10), 947\u2013957 (2009).","journal-title":"N. Engl. J. Med."},{"issue":"27","key":"13102_CR7","doi-asserted-by":"publisher","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","volume":"31","author":"LV Sequist","year":"2013","unstructured":"Sequist, L. V. et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J. Clin. Oncol. 31(27), 3327\u20133334 (2013).","journal-title":"J. Clin. Oncol."},{"key":"13102_CR8","doi-asserted-by":"crossref","unstructured":"Lee, C.K. et al. Gefitinib or Erlotinib vs chemotherapy for EGFR mutation-positive lung cancer: individual patient data meta-analysis of overall survival. J. Natl. Cancer Inst. 109(6), (2017).","DOI":"10.1093\/jnci\/djw279"},{"issue":"9","key":"13102_CR9","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","volume":"4","author":"DA Cross","year":"2014","unstructured":"Cross, D. A. et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 4(9), 1046\u20131061 (2014).","journal-title":"Cancer Discov."},{"issue":"7","key":"13102_CR10","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa1612674","volume":"376","author":"TS Mok","year":"2017","unstructured":"Mok, T. S. et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N. Engl. J. Med. 376(7), 629\u2013640 (2017).","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"13102_CR11","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","volume":"382","author":"SS Ramalingam","year":"2020","unstructured":"Ramalingam, S. S. et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N. Engl. J. Med. 382(1), 41\u201350 (2020).","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"13102_CR12","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"JC Soria","year":"2018","unstructured":"Soria, J. C. et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N. Engl. J. Med. 378(2), 113\u2013125 (2018).","journal-title":"N. Engl. J. Med."},{"issue":"10027","key":"13102_CR13","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","volume":"387","author":"RS Herbst","year":"2016","unstructured":"Herbst, R. S. et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387(10027), 1540\u20131550 (2016).","journal-title":"Lancet"},{"issue":"10066","key":"13102_CR14","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","volume":"389","author":"A Rittmeyer","year":"2017","unstructured":"Rittmeyer, A. et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389(10066), 255\u2013265 (2017).","journal-title":"Lancet"},{"issue":"21","key":"13102_CR15","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","volume":"372","author":"EB Garon","year":"2015","unstructured":"Garon, E. B. et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 372(21), 2018\u20132028 (2015).","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"13102_CR16","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei, H. et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373(17), 1627\u20131639 (2015).","journal-title":"N. Engl. J. Med."},{"key":"13102_CR17","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.lungcan.2017.11.009","volume":"115","author":"RA Soo","year":"2018","unstructured":"Soo, R. A. et al. Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions. Lung Cancer 115, 12\u201320 (2018).","journal-title":"Lung Cancer"},{"issue":"18","key":"13102_CR18","doi-asserted-by":"publisher","first-page":"4585","DOI":"10.1158\/1078-0432.CCR-15-3101","volume":"22","author":"JF Gainor","year":"2016","unstructured":"Gainor, J. F. et al. EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: A retrospective analysis. Clin. Cancer Res. 22(18), 4585\u20134593 (2016).","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"13102_CR19","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jtho.2016.10.007","volume":"12","author":"CK Lee","year":"2017","unstructured":"Lee, C. K. et al. Checkpoint inhibitors in metastatic EGFR-mutated non-small cell lung cancer-a meta-analysis. J. Thorac. Oncol. 12(2), 403\u2013407 (2017).","journal-title":"J. Thorac. Oncol."},{"key":"13102_CR20","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.ejca.2019.10.019","volume":"124","author":"CY Yang","year":"2020","unstructured":"Yang, C. Y. et al. Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors. Eur. J. Cancer 124, 110\u2013122 (2020).","journal-title":"Eur. J. Cancer"},{"issue":"2","key":"13102_CR21","doi-asserted-by":"publisher","first-page":"699","DOI":"10.21037\/tlcr-20-893","volume":"10","author":"M Kang","year":"2021","unstructured":"Kang, M. et al. Programmed death-ligand 1 expression level as a predictor of EGFR tyrosine kinase inhibitor efficacy in lung adenocarcinoma. Transl. Lung Cancer Res. 10(2), 699\u2013711 (2021).","journal-title":"Transl. Lung Cancer Res."},{"issue":"11","key":"13102_CR22","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1016\/j.jtho.2018.07.016","volume":"13","author":"S Su","year":"2018","unstructured":"Su, S. et al. Strong programmed death ligand 1 expression predicts poor response and de novo resistance to EGFR tyrosine kinase inhibitors among NSCLC patients with EGFR mutation. J. Thorac. Oncol. 13(11), 1668\u20131675 (2018).","journal-title":"J. Thorac. Oncol."},{"key":"13102_CR23","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.lungcan.2018.11.021","volume":"127","author":"KH Hsu","year":"2019","unstructured":"Hsu, K. H. et al. High PD-L1 expression correlates with primary resistance to EGFR-TKIs in treatment na\u00efve advanced EGFR-mutant lung adenocarcinoma patients. Lung Cancer 127, 37\u201343 (2019).","journal-title":"Lung Cancer"},{"issue":"1","key":"13102_CR24","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.jtho.2019.09.009","volume":"15","author":"H Brown","year":"2020","unstructured":"Brown, H. et al. Programmed cell death ligand 1 expression in untreated egfr mutated advanced NSCLC and response to osimertinib versus comparator in FLAURA. J. Thorac. Oncol. 15(1), 138\u2013143 (2020).","journal-title":"J. Thorac. Oncol."},{"key":"13102_CR25","doi-asserted-by":"crossref","unstructured":"Eisenhauer, E.A. et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur. J. Cancer 45(2), 228\u201347 (2009).","DOI":"10.1016\/j.ejca.2008.10.026"},{"issue":"3","key":"13102_CR26","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1183\/09031936.00043511","volume":"39","author":"TH Tsai","year":"2012","unstructured":"Tsai, T. H. et al. RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer. Eur. Respir. J. 39(3), 677\u2013684 (2012).","journal-title":"Eur. Respir. J."},{"issue":"4","key":"13102_CR27","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1200\/JCO.2011.38.3224","volume":"30","author":"KY Su","year":"2012","unstructured":"Su, K. Y. et al. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. J. Clin. Oncol. 30(4), 433\u2013440 (2012).","journal-title":"J. Clin. Oncol."},{"key":"13102_CR28","doi-asserted-by":"publisher","first-page":"8273","DOI":"10.2147\/OTT.S271011","volume":"13","author":"BW Yoon","year":"2020","unstructured":"Yoon, B. W., Chang, B. & Lee, S. H. High PD-L1 expression is associated with unfavorable clinical outcome in EGFR-mutated lung adenocarcinomas treated with targeted therapy. Onco. Targets Ther. 13, 8273\u20138285 (2020).","journal-title":"Onco. Targets Ther."},{"issue":"1","key":"13102_CR29","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12957-021-02254-x","volume":"19","author":"Z Peng","year":"2021","unstructured":"Peng, Z., Lin, H., Zhou, K., Deng, S. & Mei, J. Predictive value of pretreatment PD-L1 expression in EGFR-mutant non-small cell lung cancer: A meta-analysis. World. J. Surg. Oncol. 19(1), 145 (2021).","journal-title":"World. J. Surg. Oncol."},{"issue":"12","key":"13102_CR30","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1016\/j.jtho.2017.07.032","volume":"12","author":"J Zhong","year":"2017","unstructured":"Zhong, J. et al. Potential resistance mechanisms revealed by targeted sequencing from lung adenocarcinoma patients with primary resistance to epidermal growth factor receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs). J. Thorac. Oncol. 12(12), 1766\u20131778 (2017).","journal-title":"J. Thorac. Oncol."},{"issue":"4","key":"13102_CR31","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/nm.2713","volume":"18","author":"KP Ng","year":"2012","unstructured":"Ng, K. P. et al. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat. Med. 18(4), 521\u2013528 (2012).","journal-title":"Nat. Med."},{"issue":"7","key":"13102_CR32","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1172\/JCI73048","volume":"124","author":"KS Park","year":"2014","unstructured":"Park, K. S. et al. CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance. J. Clin. Invest. 124(7), 3003\u20133015 (2014).","journal-title":"J. Clin. Invest."},{"issue":"18","key":"13102_CR33","doi-asserted-by":"publisher","first-page":"4579","DOI":"10.1158\/1078-0432.CCR-18-0267","volume":"24","author":"M Saigi","year":"2018","unstructured":"Saigi, M. et al. MET-oncogenic and JAK2-inactivating alterations are independent factors that affect regulation of PD-L1 expression in lung cancer. Clin. Cancer. Res. 24(18), 4579\u20134587 (2018).","journal-title":"Clin. Cancer. Res."},{"issue":"6","key":"13102_CR34","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1097\/JTO.0000000000000500","volume":"10","author":"N Chen","year":"2015","unstructured":"Chen, N. et al. Upregulation of PD-L1 by EGFR activation mediates the immune escape in EGFR-driven NSCLC: Implication for optional immune targeted therapy for NSCLC Patients with EGFR mutation. J. Thorac. Oncol. 10(6), 910\u2013923 (2015).","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"13102_CR35","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jtho.2016.11.2228","volume":"12","author":"FR Hirsch","year":"2017","unstructured":"Hirsch, F. R. et al. PD-L1 immunohistochemistry assays for lung cancer: Results from phase 1 of the blueprint PD-L1 IHC assay comparison project. J. Thorac. Oncol. 12(2), 208\u2013222 (2017).","journal-title":"J. Thorac. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-13102-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-13102-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-13102-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T05:22:11Z","timestamp":1669353731000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-13102-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,13]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["13102"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-13102-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,13]]},"assertion":[{"value":"12 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9753"}}